Dihydroquinone Ansamycins: Toward Resolving the Conflict between Low in Vitro Affinity and High Cellular Potency of Geldanamycin Derivatives
Anna C. Maroney(AbbVie (United States)), Dana L. Johnson(Johnson & Johnson (United States)), Larry E. Weaner(Johnson & Johnson (United States)), Thomas Garrabrant(Johnson & Johnson (United States)), Holly K. Koblish(Wilmington University), John A. Masucci(Johnson & Johnson (United States)), Robert A. Galemmo(Johnson & Johnson (United States)), Ingrid C. Deckman(Johnson & Johnson (United States)), Alexander N. Barnakov(Johnson & Johnson (United States)), Juan Marugán(National Institutes of Health), Ludmila A. Barnakova(Johnson & Johnson (United States)), William J. Jones(Johnson & Johnson (United States)), Matthew J. Todd(ALS Biopharma (United States)), Tara M. Mezzasalma(Johnson & Johnson (United States))
Cited by 54
Related Papers
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
|Journal of Medicinal Chemistry|2005|430
Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway
|Journal of Neuroscience|1998|293
The MLK Family Mediates c-Jun N-Terminal Kinase Activation in Neuronal Apoptosis
|Molecular and Cellular Biology|2001|268
beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation
|Journal of Neurochemistry|2001|223